// App-Quantinova.ai

: Cost-Effectiveness of Blinatumomab Versus Standard of Care in Adult Patients with Philadelphia-Chromosome-Negative B-Precursor Acute Lymphoblastic Leukemia in First Hematological Complete Remission (CR) with Minimal Residual Disease (MRD) from a US Payer Perspective

Researchers

Presenter

  • Thomas Delea

Principal Investigators

  • Nicholas Despiegel

  • Diana Boyko

  • Jordan Amdahl

  • Ze Cong

  • Jerald Radich

Medical Centers

  • Policy Analysis Inc. (PAI), Brookline, MA

  • Amgen Inc, Thousand Oaks, CA

  • Global Health Economics, Amgen Inc., South San Francisco, CA

  • Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA

Locations

  • United States

Companies

  • Amgen Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • Breakpoint Cluster Region

Drug/Treatment

  • Blinatumomab

Outcome

  • N/A

Study Design

  • Observational

  • Cohort

Phase

  • II

Study Id's

  • NCT01207388

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved